Clover Biopharmaceuticals Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites
Tuesday, June 19, 2018
Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I trial of SCB-313, an investigational fully-human TRAIL-Trimer fusion protein, for the treatment of cancer patients with malignant ascites.
“We are extremely excited about the initiation of the SCB-313 study for malignant ascites. This milestone marks the successful and complete transition of Clover into a global, clinical-stage biotechnology company,” said Joshua Liang, Chief Strategy Officer and Board Director at Clover. “The treatment of malignant ascites remains a high unmet need globally, with no targeted or biologic antitumor therapies currently approved and available, and we hope that SCB-313 will provide a safe and efficacious option for patients worldwide.”
The Phase I, open-label, dose escalation, multi-center trial in Australia is designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of intraperitoneally administered SCB-313 as a single-agent for the treatment of malignant ascites.
“We believe that SCB-313 has the potential to be a first-in-class and best-in-class TRAIL-based therapy based on our preclinical results to date,” said Dr. Peng Liang, co-founder, Chairman and President of Clover. “TRAIL has long been considered a tantalizing target for cancer therapy because it can induce apoptosis in a tumor-specific manner across many different tumor types. SCB-313, which utilizes our proprietary Trimer-Tag© technology, is able to potently and uniquely target this trimerization-dependent pathway. As our first drug candidate utilizing Trimer-Tag© technology to enter human clinical trials, SCB-313 is yet another validation of our translational research capabilities, and we look forward to advancing our other promising biological candidates in the months ahead.”
